Thromb Haemost 2004; 91(02): 300-307
DOI: 10.1160/TH03-07-0419
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Local INR calibration of the Owren type prothrombin assay greatly improves the intra- and interlaboratory variation

A three-year follow-up from the Swedish national external quality assessment scheme
Andreas Hillarp
1   Department of Clinical Chemistry at Malmö University Hospital, Malmö, Gothenburg, Sweden
,
Nils Egberg
2   Department of Karolinska Hospital, Stockholm, Gothenburg, Sweden
,
Gunnar Nordin
3   Equalis AB, Uppsala, Sahlgrenska University Hospital, Gothenburg, Sweden
,
Lennart Stigendal
4   Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden
,
Inger Fagerberg
5   Department of Sahlgrenska University Hospital, Gothenburg
,
Tomas L. Lindahl
6   University Hospital of Linköping, Sahlgrenska University Hospital, Gothenburg, Sweden
› Author Affiliations
Further Information

Publication History

Received 01 July 2003

Accepted after revision 30 January 2003

Publication Date:
01 December 2017 (online)

Summary

In 1999, a simplified procedure for calibration of the Owren prothrombin time (Owren PT) assay was introduced by a working group of the organisation for national quality assurance in laboratory medicine in Sweden. The new protocol allowed local calibration by means of only two lyophilised national plasma calibrators and expression of results as an international normalized ratio (INR). This is our report of a three-year follow-up involving the analysis of data from all laboratories, in hospitals (n=88 in 2002) and primary health care units (n=246 in 2002) that perform the Owren PT assay in Sweden. The interlaboratory variation was significantly improved after the introduction of the new calibration procedure. For the larger hospital-based laboratories, the mean coefficient of variation (CV) was reduced from 7.9% to 5.2% (p<0.0001) when analysing test materials with INR range 2-4. In the higher INR range (>4), the CV was reduced even further, from 10.4% to 6.8% (p<0.0001). The corresponding results from smaller laboratories in the primary health care units showed a similar decrease in CV from 8.2% to 5.7% in the INR range 2-4 (p<0.0001). At the INR range >4, the CV was reduced from 9.5% to 7.8%. The intralaboratory variation was also improved for both types of laboratory categories. This study shows an improved precision, with CV less than 6% at the therapeutic INR range, for both hospital-based laboratories and smaller laboratories in the primary health care system. The results indicate that the Owren PT assay is well suited for local INR calibration employing only two calibrant plasmas in a simplified procedure.

 
  • References

  • 1 Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and jaundice. Am J Med Sci 1935; 190: 501-11.
  • 2 Quick AJ. The prothrombin time in hemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 73-4.
  • 3 Owren PA, Aas K. The control of Dicumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand J Clin Invest 1951; 03: 201-8.
  • 4 Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 1959; ii: 754-8.
  • 5 W.H.O.Expert Committee on Biological Standardisation. Requirements for thromboplastins and plasmas used to control oral anticoagulant therapy. 33rd Report. W.H.O. Technical Report Series 1983; 687: 81-105.
  • 6 Lindahl TL, Egberg N, Hillarp A, Ødegaard RO, Edlund B, Svensson J, Sandset PM, Rånby M. INR calibration of Owren type prothrombin time based on the relationship between PT% and INR utilizing normal plasma samples.. In press.
  • 7 W.H.O. Expert Committee on Biological Standardisation. Guidelines for thromboplastins and plasma used to control oral anticoagulant therapy. W.H.O. Technical Report Series No 889; Geneva: 1999
  • 8 van den Besselaar AM. International Standardisation of laboratory control of oral anticoagulant therapy: a survey of thromboplastin reagents used for prothrombin time testing. J Heart Valve Dis 1993; 02: 42-52.
  • 9 Ng VL, Levin J, Corash L, Gottfried EL. Failure of international normalized ratio to generate consistent results within a local medical community. Am J Clin Pathol 1993; 99: 653-5.
  • 10 van Rijn JL, Schmidt NA, Rutten WP. Correction of instrument- and reagent-based differences in determination of the international normalized ratio (INR) for monitoring anticoagulant therapy. Clin Chem 1989; 35: 840-3.
  • 11 Cunningham MT, Johnson GF, Pennell BJ, Olson JD. The reliability of manufacturerdetermined, instrument-specific international sensitivity index values for calculating the international normalised ratio. Am J Clin Pathol 1994; 102: 128-33.
  • 12 Adcock DM, Duff S. Enhanced standardisation of the international normalized ratio through the use of plasma calibrants: a concise review. Blood Coagul Fibrinolysis 2000; 11: 583-90.
  • 13 Horsti J. Has the Quick or the Owren prothrombin time method the advantage in harmonization for the international normalised ratio system?. Blood Coagul Fibrinolysis 2002; 13: 641-6.
  • 14 Horsti J. Agreement of Owren and Quick prothrombin times: effects of citrate and calcium concentrations and international sensitivity index correction. Clin Chem 2001; 47: 940-4.
  • 15 Houbouyan LL, Gougel AF. Long-term French experience in INR standardization by a procedure using plasma calibrants. Am J Clin Pathol 1997; 108: 83-9.
  • 16 Kitchen S, Jennings I, Woods TAL, Preston FE. Local calibration of international normalised ratio improves between laboratory agreement: Results from the UK national external quality assessment scheme. Thromb Haemost 1999; 81: 60-5.
  • 17 Brien WF, Baskerville JC, Taberner DA, Crawford L. Calculation vs calibration curve for INR determination. Results from an interlaboratory proficiency scheme. Am J Pathol 1999; 111: 193-201.
  • 18 Chantarangkul V, Tripodi A, Cesana BM, Mannucci PM. Calibration of local systems with lyophilised calibrant plasmas improves interlaboratory variability of the INR in the Italian external quality assessment scheme. Thromb Haemost 1999; 82: 1621-6.